Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06394739 · ClinicalTrials.gov registry record

RevCore for In Stent Thrombosis

A clinical trial of In-stent Thrombosis, sponsored by Inari Medical.

Recruiting
Registry status
100
Enrollment target
15
Study locations

NCT06394739 is a study of In-stent Thrombosis that is actively recruiting participants, run by Inari Medical. The registered enrollment target is 100 participants. The trial reports 15 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06394739, a study of In-stent Thrombosis, is actively recruiting participants, sponsored by Inari Medical.

RECRUITING
Registry status
100 participants
Enrollment target
15
Study locations

Study Summary

The purpose of this research is to collect information about how the RevCore Thrombectomy Catheter works to treat stent blockages.

Conditions Studied

Interventions

  • DEVICE Thrombectomy

Study Locations (15)

Pennsylvania

  • University of Pennsylvania - Philadelphia
  • Thomas Jefferson University - Philadelphia
  • Allegheny Health Network Research Institute - Pittsburgh

Ohio

  • UH Cleveland Medical Center - Cleveland
  • Ohio State University - Columbus

Connecticut

  • Yale University - New Haven

District of Columbia

  • Medstar Health Research Institute - Washington D.C.

Maryland

  • University of Maryland - Baltimore

New York

  • New York University- Langone - New York

North Carolina

  • Mission Health - Asheville

South Carolina

  • Spartanburg Medical Center - Spartanburg

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2024-09-09
Est. Completion 2028-04

Sponsor

Inari Medical

12 total trials

What the Registry Record Tells You About NCT06394739

The ClinicalTrials.gov registry entry for NCT06394739 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inari Medical, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with In-stent Thrombosis appearing as the primary indexed condition, and to 1 intervention - of which Thrombectomy is the first listed.

NCT06394739 reports 15 study locations spanning 12 distinct geographic areas - top geographies include Pennsylvania, Ohio, Connecticut.

Frequently Asked Questions

What is clinical trial NCT06394739 about?

NCT06394739 is a clinical study titled "RevCore for In Stent Thrombosis". The purpose of this research is to collect information about how the RevCore Thrombectomy Catheter works to treat stent blockages.

What is the current status of trial NCT06394739?

This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2024-09-09. Estimated completion is 2028-04.

What conditions does trial NCT06394739 study?

This clinical trial studies the following conditions: In-stent Thrombosis.

What interventions are being tested in trial NCT06394739?

The interventions under investigation include: Thrombectomy (DEVICE).

Who is sponsoring clinical trial NCT06394739?

This trial is sponsored by Inari Medical, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06394739 being conducted?

This trial has 15 study locations across Connecticut, District of Columbia, Maryland, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.